- view fewer
Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.
4005 - 4016.
We previously reported that rOv-ASP-1, a recombinant Onchocerca volvulus activation associated protein-1, was a potent adjuvant for recombinant protein or synthetic peptide-based Ags. In this study, we further evaluated the adjuvanticity of rOv-ASP-1 and explored its mechanism of action. Consistently, recombinant full-length spike protein of SARS-CoV or its receptor-binding domain in the presence of rOv-ASP-1 could effectively induce a mixed but Th1-skewed immune response in immunized mice. It appears that rOv-ASP-1 primarily bound to the APCs among human PBMCs and triggered Th1-biased proinflammatory cytokine production probably via the activation of monocyte-derived dendritic cells and the TLR, TLR2, and TLR4, thus suggesting that rOv-ASP-1 is a novel potent innate adjuvant.
|Title:||Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.|
|Keywords:||Adjuvants, Immunologic, Animals, Antigen Presentation, Antigen-Presenting Cells, Antigens, Helminth, Cytokines, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Helminth Proteins, Humans, Lymphocyte Activation, Membrane Glycoproteins, Mice, Recombinant Proteins, Spike Glycoprotein, Coronavirus, Th1 Cells, Th2 Cells, Toll-Like Receptor 2, Toll-Like Receptor 4, Viral Envelope Proteins|
Archive Staff Only